An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy.

  1. Blaye, C, Darbo, É, Debled, M, Brouste, V, Vélasco, V, Pinard, C et al.. An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. ESMO Open. 2022;7 (4):100502. doi: 10.1016/j.esmoop.2022.100502. PubMed PMID:35759853 PubMed Central PMC9434232.
Search PubMed

People Involved

All right reserved © immunoconcept.cnrs.fr 2022 by Nivo-Web

Scroll to Top